By Michael B. Goodkin MD, FACC
Although a great majority of ivermectin-based studies have indicated real promise, one particular study conducted by a small trial site in Colombia received unprecedented media attention when the study results indicated negligible impact. What hasn’t been disclosed by media is the seriously questionable pharmaceutical industry support of this one trial site. During the study, a handful of some of the largest drug companies in the world gave this site money. What’s not clear is why this occurred and whether the funds are correlated to some nefarious agenda. This author suggests that the publisher should have scrutinized this industry funding perhaps more carefully.
On March 4th, 2021, an article appeared in JAMA titled, "Effect of Ivermectin On Time To Resolution of Symptoms Among Adults With Mild COVID." It concluded, "The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes."
Dr. Eduardo Lopez-Medina et al. from Cali, Colombia, randomized 400 mildly ill patients, averaging 37 years ol...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).